TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04353180
Drug: Aerosolized 13 cis retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
Study: NCT06254014
Drug: Exendin-4 Fc fusion protein injection
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
Study: NCT06254014
Drug: Exendin-4 Fc fusion protein injection
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
Study: NCT05943613
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section
Study: NCT04772729
Drug: Insulin faster aspart (Fiasp, Novo Nordisk)
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent.
Study: NCT04887493
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 25µg will be used for both the study arms
Study: NCT06280482
Drug: Nicotinamide riboside (NR)
Normalized name: nicotinamide ribotide
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
Study: NCT04820309
Drug: Xanomeline and Trospium Chloride Capsules
Normalized name: trospium chloride / xanomeline Pill
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
Study: NCT06487585
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
Study: NCT04730843
Drug: ES102
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
Study: NCT05389722
Drug: CC-92480
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05389722
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05389722
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05389722
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03976973
Drug: Bromelain
Normalized name: Bromelain
DrugBank: Bromelains (DB13281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
Study: NCT03976973
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
Study: NCT06063200
Drug: Methylphenidate Pill
Normalized name: methylphenidate Pill
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single encapsulated pill
Study: NCT05944757
Drug: PRP plasma rich platelets
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty patients (20) underwent 0.5 ml 100 % intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
Study: NCT05944757
Drug: Autologous serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty patients (20) underwent intrastromal injection of 0.5 ml 100 %of autologous serum (second group) every 2 weeks for 1 month
Study: NCT04873245
Drug: Semaglutide and Behavioral Program
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants randomized to this group will receive semaglutide and behavioral therapy.
Study: NCT06654960
Drug: Metformin Hydrochloride tablets
Normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride tablets 500mg.
Study: NCT05182957
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
Study: NCT04505189
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin assisted psychotherapy
Study: NCT05182957
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg qd po d1-d10 (/21d)
Study: NCT05182957
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75mg/m2 i.v d1-d7 (/21d)
Study: NCT06301334
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group CTB (n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25% Group ESPB (n=30): patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
Study: NCT06539013
Drug: N2O
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of N2O for analgesia
Study: NCT05299437
Drug: Radioiodine optimized therapy
Normalized name: Monistat Simple Therapy
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status.
Study: NCT05912062
Drug: Trastuzumab (neoadjuvant)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
Study: NCT05912062
Drug: Pertuzumab (neoadjuvant)
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
Study: NCT05912062
Drug: Paclitaxel (neoadjuvant)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
Study: NCT04850755
Drug: Selinexor in combination with nivolumab and ipilimumab
Normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
Study: NCT00085761
Drug: Capsaicin Dermal Patch
Normalized name: capsaicin Medicated Patch
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05464303
Drug: Intravenous Antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
Study: NCT00720603
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
Study: NCT06375109
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered via Intravenous (IV) injection
Study: NCT06375109
Drug: Carboplatin injection
Normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered via IV injection
Study: NCT06375109
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered via IV injection
Study: NCT06375109
Drug: Etoposide injection
Normalized name: etoposide Injection
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered via IV injection
Study: NCT05012254
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion.
Study: NCT05012254
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion.
Study: NCT05012254
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center.
Study: NCT04597723
Drug: oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given different concentrations of oxygen.
Study: NCT05748093
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.
Study: NCT05012254
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center.
Study: NCT05951608
Drug: AK127 in combination with AK112
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years
Study: NCT00002307
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002307
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05012254
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Study: NCT05079503
Drug: GEN-001
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
Study: NCT05012254
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol \[2,3 d\]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center
Study: NCT04952857
Drug: cholecalciferol 6 lakh IU
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D levels and serum calcium will be assessed at day 3,7, 14.
Study: NCT06654596
Drug: Telitacicept 240mg
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.
Study: NCT04804254
Drug: ABBV-623
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets
Study: NCT04804254
Drug: ABBV-992
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets
Study: NCT06202755
Drug: Ticagrelor 90 MG
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT05913414
Drug: Iron Isomaltoside 1000
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Iron isomaltoside after IC and CCRT
Study: NCT06202755
Drug: Cilostazol 100 MG
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT06020456
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
Study: NCT03948022
Drug: Dydrogesterone 10Mg Tablet (duphaston)
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg daily oral tablets
Study: NCT03948022
Drug: Progesterone 50Mg/mL Oil
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg daily intramuscular injections
Study: NCT05748990
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
Study: NCT05098041
Drug: Soticlestat
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat tablets.
Study: NCT05819918
Drug: Calcifediol
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects hospitalized with COVID-19 treated with calcifediol
Study: NCT05098041
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin capsules.
Study: NCT05875675
Drug: Drug: Pioglitazone Oral Tablet
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Supplement: Pioglitazone 30 mg by mouth daily
Study: NCT04688203
Drug: Magnesium Sulfate Injection
Normalized name: magnesium sulfate Injection
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
Study: NCT04688203
Drug: Labetalol Injectable Solution
Normalized name: labetalol Injectable Solution
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
Study: NCT06220162
Drug: chidamide in combination with venetoclax and azacitidine (VAC)
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enrolled patients were given chidamide 10 mg every day on days 1-14, azacitidine 75mg/m2 every day on days 1-7, and oral venetoclax began at 100mg on day 1 and increased stepwise over 3 days to reach the target dose of 400mg (100mg, 200mg, and 400mg) on days 1-28. Dose adjustments for concomitant venetoclax with CYP3A4 inhibitors were made according to the literature.
Study: NCT05296746
Drug: Chemotherapy (adjuvant)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy. 3 regimens are permitted.
Study: NCT05296746
Drug: Ribociclib (adjuvant)
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
Study: NCT06780098
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05875506
Drug: Ozone gel
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
Study: NCT05268926
Drug: Dapagliflozin 10Mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dapagliflozin 10 mg/d or matched placebo
Study: NCT05279846
Drug: Vehicle (Placebo Comparator)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically for 48 weeks
Study: NCT05034965
Drug: hyaluronic acid filler injection
Normalized name: undecylenic acid Topical Spray [Hongo Killer]
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quantitative surface electromyography before injection(baseline) and one week after injection